Patents by Inventor Takatsugu INOUE
Takatsugu INOUE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200354358Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: July 24, 2020Publication date: November 12, 2020Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Patent number: 10781210Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, —A— is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: GrantFiled: November 15, 2019Date of Patent: September 22, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Takatsugu Inoue, Motohiro Fujiu
-
Patent number: 10640495Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.Type: GrantFiled: July 6, 2016Date of Patent: May 5, 2020Assignee: Shionogi & Co., Ltd.Inventors: Akira Yukimasa, Kenichiroh Nakamura, Masanao Inagaki, Kazuya Kano, Motohiro Fujiu, Hiroki Yamaguchi, Kayoko Hata, Takatsugu Inoue
-
Publication number: 20200087302Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: November 15, 2019Publication date: March 19, 2020Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Publication number: 20190062282Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: ApplicationFiled: October 31, 2018Publication date: February 28, 2019Applicant: Shionogi & Co., Ltd.Inventors: Akira YUKIMASA, Kenichiroh NAKAMURA, Tohru HORIGUCHI, Kazuya KANO, Takatsugu INOUE
-
Publication number: 20190047998Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, -A- is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.Type: ApplicationFiled: February 3, 2017Publication date: February 14, 2019Inventors: Akira YUKIMASA, Kazuya KANO, Tohru HORIGUCHI, Kenichiroh NAKAMURA, Takatsugu INOUE, Motohiro FUJIU, Hiroki YAMAGUCHI
-
Patent number: 10160727Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: GrantFiled: August 5, 2015Date of Patent: December 25, 2018Assignee: Shionogi & Co., Ltd.Inventors: Kenichiroh Nakamura, Takatsugu Inoue
-
Patent number: 10150728Abstract: The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is —O—(CR6R7)m- etc., -L2- is —O—(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc.Type: GrantFiled: October 17, 2014Date of Patent: December 11, 2018Assignee: SHIONOGI & CO., LTD.Inventors: Naotake Kobayashi, Kentarou Asahi, Yutaka Tomida, Masahide Ohdan, Masataka Fumoto, Yoshikazu Sasaki, Kana Kurahashi, Takatsugu Inoue, Tomomi Urabe, Yuji Nishiura, Masafumi Iwatsu, Keisuke Miyazaki, Naoki Ohyabu, Toshihiro Wada, Manabu Katou
-
Publication number: 20180201607Abstract: The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a single bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, and the group represented by is a group represented by Formula: or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.Type: ApplicationFiled: July 6, 2016Publication date: July 19, 2018Inventors: Akira YUKIMASA, Kenichiroh NAKAMURA, Masanao INAGAKI, Kazuya KANO, Motohiro FUJIU, Hiroki YAMAGUCHI, Kayoko HATA, Takatsugu INOUE
-
Publication number: 20170240512Abstract: The present invention relates to a compound represented by Formula (I): wherein -L- is —C(?X)—, or the like, —Z— is —NR5—, or the like, —ZA— is —NR5A—, or the like, —W— is —C(R8R9)n-, —WA— is —C(R3R4)m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: ApplicationFiled: August 5, 2015Publication date: August 24, 2017Applicant: Shionogi & Co., Ltd.Inventors: Akira YUKIMASA, Iori KOZONO, Kenichiroh NAKAMURA, Tohru HORIGUCHI, Kazuya KANO, Takatsugu INOUE
-
Patent number: 9708338Abstract: The present invention is related to a compound represented by formula (I) wherein —X— is —NH— or —S—; —Z— is —O— or —S—; R3, R5 and R6 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R7 is a cyano, substituted or unsubstituted amino, or the like; R7? is each independently a halogen; b is 0 or 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: GrantFiled: March 22, 2016Date of Patent: July 18, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Akira Yukimasa, Naoki Tsuno, Motohiro Fujiu, Hiroki Yamaguchi, Hiromi Kudo, Tatsuhiko Ueno, Yusuke Ichihashi, Takatsugu Inoue, Shinji Suzuki
-
Publication number: 20160257641Abstract: The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is —O—(CR6R7)m- etc., -L2- is —O—(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc.Type: ApplicationFiled: October 17, 2014Publication date: September 8, 2016Applicant: Shionogi & Co., Ltd.Inventors: Naotake KOBAYASHI, Kentarou ASAHI, Yutaka TOMIDA, Masahide OHDAN, Masataka FUMOTO, Yoshikazu SASAKI, Kana KURAHASHI, Takatsugu INOUE, Tomomi URABE, Yuji NISHIURA, Masafumi IWATSU, Keisuke MIYAZAKI, Naoki OHYABU, Toshihiro WADA, Manabu KATOU
-
Publication number: 20160200721Abstract: The present invention is related to a compound represented by formula (I) wherein —X— is —NH— or —S—; —Z— is —O— or —S—; R3, R5 and R6 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R7 is a cyano, substituted or unsubstituted amino, or the like; R7? is each independently a halogen; b is 0 or 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.Type: ApplicationFiled: March 22, 2016Publication date: July 14, 2016Applicant: Shionogi & Co., Ltd.Inventors: Akira YUKIMASA, Naoki TSUNO, Motohiro FUJIU, Hiroki YAMAGUCHI, Hiromi KUDO, Tatsuhiko UENO, Yusuke ICHIHASHI, Takatsugu INOUE, Shinji SUZUKI